302 related articles for article (PubMed ID: 29665189)
21. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation.
O'Leary JG; Kaneku H; Jennings LW; Bañuelos N; Susskind BM; Terasaki PI; Klintmalm GB
Liver Transpl; 2013 Sep; 19(9):973-80. PubMed ID: 23780820
[TBL] [Abstract][Full Text] [Related]
22. Donor-specific anti-HLA antibodies are not associated with nonanastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation.
den Dulk AC; Shi X; Verhoeven CJ; Dubbeld J; Claas FHJ; Wolterbeek R; Brand-Schaaf SH; Verspaget HW; Sarasqueta AF; van der Laan LJW; Metselaar HJ; van Hoek B; Kwekkeboom J; Roelen DL
Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29193362
[TBL] [Abstract][Full Text] [Related]
23. Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation.
Wozniak LJ; Hickey MJ; Venick RS; Vargas JH; Farmer DG; Busuttil RW; McDiarmid SV; Reed EF
Transplantation; 2015 Jul; 99(7):1416-22. PubMed ID: 26038872
[TBL] [Abstract][Full Text] [Related]
24. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
[TBL] [Abstract][Full Text] [Related]
25. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
[TBL] [Abstract][Full Text] [Related]
26. Clinical Significance of Alloantibodies in Hand Transplantation: A Multicenter Study.
Berglund E; Andersen Ljungdahl M; Bogdanović D; Berglund D; Wadström J; Kowalski J; Brandacher G; Kamińska D; Kaufman CL; Talbot SG; Azari K; Landin L; Höhnke C; Dwyer KM; Cavadas PC; Thione A; Clarke B; Kay S; Wilks D; Iyer S; Iglesias M; Özkan Ö; Özkan Ö; Krapf J; Weissenbacher A; Petruzzo P; Schneeberger S
Transplantation; 2019 Oct; 103(10):2173-2182. PubMed ID: 30817406
[TBL] [Abstract][Full Text] [Related]
27. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
[TBL] [Abstract][Full Text] [Related]
28. Characteristics and predictive value for graft fibrosis of the complement-binding capacity of donor-specific human leukocyte antigen antibodies after pediatric liver transplantation.
Tokodai K; Miyagi S; Nakanishi W; Nishimura R; Fujio A; Goto M; Unno M; Kamei T
Pediatr Transplant; 2020 Feb; 24(1):e13648. PubMed ID: 31885148
[TBL] [Abstract][Full Text] [Related]
29. De Novo Donor-Specific Anti-Human Leukocyte Antigen Antibody Detection in Long-Term Adult Liver Transplantation.
San Segundo D; Alonso C; Ruiz P; Romon I; Arias-Loste MT; Cuadrado A; Puente A; Casafont F; López-Hoyos M; Crespo J; Fábrega E
Transplant Proc; 2016 Nov; 48(9):2980-2982. PubMed ID: 27932124
[TBL] [Abstract][Full Text] [Related]
30. Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies.
Ixtlapale-Carmona X; Arvizu A; De-Santiago A; González-Tableros N; López M; Castelán N; Marino LA; Uribe-Uribe NO; Contreras AG; Vilatobá M; Morales-Buenrostro LE; Alberú J
Transpl Immunol; 2018 Feb; 46():8-13. PubMed ID: 28974434
[TBL] [Abstract][Full Text] [Related]
31. Long-term Clinical Relevance of De Novo Donor-Specific Antibodies After Pediatric Liver Transplantation.
Grabhorn E; Binder TM; Obrecht D; Brinkert F; Lehnhardt A; Herden U; Peine S; Nashan B; Ganschow R; Briem-Richter A
Transplantation; 2015 Sep; 99(9):1876-81. PubMed ID: 25706279
[TBL] [Abstract][Full Text] [Related]
32. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.
Lachmann N; Terasaki PI; Budde K; Liefeldt L; Kahl A; Reinke P; Pratschke J; Rudolph B; Schmidt D; Salama A; Schönemann C
Transplantation; 2009 May; 87(10):1505-13. PubMed ID: 19461487
[TBL] [Abstract][Full Text] [Related]
33. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
Am J Transplant; 2018 Jul; 18(7):1783-1789. PubMed ID: 29509295
[TBL] [Abstract][Full Text] [Related]
34. Pretransplant donor-specific HLA antibodies detected by single antigen bead flow cytometry: risk factors and outcomes after kidney transplantation.
Kanter Berga J; Sancho Calabuig A; Gavela Martinez E; Puig Alcaraz N; Beltran Catalan S; Avila Bernabeu A; Crespo Albiach J; Montoro JA; Pallardo Mateu LM
Transplant Proc; 2012 Nov; 44(9):2529-31. PubMed ID: 23146444
[TBL] [Abstract][Full Text] [Related]
35. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.
Cuadrado A; San Segundo D; López-Hoyos M; Crespo J; Fábrega E
World J Gastroenterol; 2015 Oct; 21(39):11016-26. PubMed ID: 26494958
[TBL] [Abstract][Full Text] [Related]
37. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation.
Song JL; Gao W; Zhong Y; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Wu H; Xu MQ; Chen ZY; Wei YG; Jiang L; Yang J
World J Gastroenterol; 2016 Feb; 22(6):2133-41. PubMed ID: 26877618
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of a Steroid Avoidance Immunosuppression Regimen in Renal Transplant Patients With De Novo or Preformed Donor-Specific Antibodies: A Single-Center Study.
Schutt R; Case J; Kurian SM; Spierling Bagsic SR; Barrick BL; Toll AE; Zhang Q; Reed EF; Quigley MM; Schaffer R; Fisher JS; Rice JC; Marsh CL
Transplant Proc; 2021 Apr; 53(3):950-961. PubMed ID: 33293041
[TBL] [Abstract][Full Text] [Related]
39. Deleterious impact of C3d-binding donor-specific anti-HLA antibodies after pediatric liver transplantation.
Couchonnal E; Rivet C; Ducreux S; Dumortier J; Bosch A; Boillot O; Collardeau-Frachon S; Dubois R; Hervieu V; André P; Scoazec JY; Lachaux A; Dubois V; Guillaud O
Transpl Immunol; 2017 Dec; 45():8-14. PubMed ID: 28782692
[TBL] [Abstract][Full Text] [Related]
40. Preformed donor-specific HLA antibodies are associated with increased risk of early mortality after liver transplantation.
McCaughan JA; Robertson V; Falconer SJ; Cryer C; Turner DM; Oniscu GC
Clin Transplant; 2016 Dec; 30(12):1538-1544. PubMed ID: 27653177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
